<p><img src="https://imageproxy.pbkrs.com/https://talkmarkets.com/user_content/ckimages/orig_mark%20hake.webp?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://talkmarkets.com/user_content/ckimages/orig_mark%20hake.webp"/></p>
<p>在他最近的文章《SenesTech 43% 的收入激增无人关注》中，TalkMarkets 作者 Mark Hake 作为对公司的研究的一部分，访问了 SenesTech（SNES）的制造设施。在这次采访中，他提供了对公司运营、产品差异化和商业模式的第一手评估。</p>
<p>讨论探讨了 SenesTech 的 Evolve 啮齿动物避孕产品如何通过抑制种群而非灭绝来创造经常性收入。管理层对话中的见解突出了生产的可扩展性、国际增长机会以及公司的现金流状况。分析还概述了 SenesTech 达到可持续现金流所需的关键风险和里程碑。</p>
<p>观看与 Mark Hake 的完整采访——讨论在 16:30 左右开始。</p>
<hr/>
<p><em>相关文章：</em></p>
<p>SenesTech 43% 的收入激增无人关注</p>
<p>SenesTech 在收入增加和全球产品分销中仍被低估</p>
<p>SenesTech 在小害虫上的大举措</p>
<p>SenesTech：一个值得关注的鲜为人知的生物科技公司</p>

SNES

<p>Mark Hake 来自 TalkMarkets，对 SenesTech 进行了工厂参观，评估其运营、产品差异化和商业模式。重点关注 SenesTech 的 Evolve 鼠类生育控制产品，该产品产生持续的收入。采访强调了生产的可扩展性、国际增长机会和财务风险。讨论了实现可持续现金流的关键里程碑。完整的采访可在 16:30 时段开始观看</p>

<p><img src="https://imageproxy.pbkrs.com/https://talkmarkets.com/user_content/ckimages/orig_mark%20hake.webp" alt="" original-src="https://talkmarkets.com/user_content/ckimages/orig_mark%20hake.webp"/></p>
<p>As part of his research into the company for his recent article, SenesTech's 43% Revenue Surge That Nobody's Talking About, TalkMarkets author Mark Hake visited SenesTech's (SNES) manufacturing facility. In this interview, he provides a firsthand assessment of the company’s operations, product differentiation, and business model.</p>
<div class="lb-trans"><p>在他最近的文章《SenesTech 43% 的收入激增无人关注》中，TalkMarkets 作者 Mark Hake 作为对公司的研究的一部分，访问了 SenesTech（SNES）的制造设施。在这次采访中，他提供了对公司运营、产品差异化和商业模式的第一手评估。</p>
</div><p>The discussion explores how SenesTech’s Evolve rodent birth control product creates recurring revenue through population suppression rather than extermination. Insights from management conversations highlight production scalability, international growth opportunities, and the company’s cash runway. The analysis also outlines key risks and the milestones required for SenesTech to reach sustainable cash flow.</p>
<div class="lb-trans"><p>讨论探讨了 SenesTech 的 Evolve 啮齿动物避孕产品如何通过抑制种群而非灭绝来创造经常性收入。管理层对话中的见解突出了生产的可扩展性、国际增长机会以及公司的现金流状况。分析还概述了 SenesTech 达到可持续现金流所需的关键风险和里程碑。</p>
</div><p>Watch the full interview with Mark Hake — the discussion begins around the 16:30 mark.</p>
<div class="lb-trans"><p>观看与 Mark Hake 的完整采访——讨论在 16:30 左右开始。</p>
</div><hr/>
<div class="lb-trans"><hr/>
</div><p><em>Related Articles:</em></p>
<div class="lb-trans"><p><em>相关文章：</em></p>
</div><p>SenesTech's 43% Revenue Surge That Nobody's Talking About</p>
<div class="lb-trans"><p>SenesTech 43% 的收入激增无人关注</p>
</div><p>SenesTech Remains Undervalued With Increasing Revenues And Global Product Distribution</p>
<div class="lb-trans"><p>SenesTech 在收入增加和全球产品分销中仍被低估</p>
</div><p>SenesTech's Big Play On Small Pests</p>
<div class="lb-trans"><p>SenesTech 在小害虫上的大举措</p>
</div><p>SenesTech: A Little-Known Biotech Company Worthy Of Attention</p>
<div class="lb-trans"><p>SenesTech：一个值得关注的鲜为人知的生物科技公司</p>
</div>

参观 SenesTech 现场工厂后的评审